SAMM50 and neoplasm: Subgroup analysis in the TRG2 and TRG3 groups separately revealed a significantly better OS for patients with MSI‐H tumours in the TRG3 group (HR, 0.43; 95% CI, 0.19–0.98, p = 0.043) (Figure 3F and Table 3).